重组人组织型纤溶酶原激酶衍生物溶栓治疗急性心肌梗死的疗效观察

东伟

（陕西省华阴市人民医院，陕西 渭南，714200）

浏览次数：168次 下载次数：408次

摘要：

目的 探讨在急性心肌梗死溶栓治疗中使用重组人组织型纤溶酶原激酶衍生物的疗效。方法 选取2012年12月至2015年12月我院收治的80例急性心肌梗死患者，按照住院顺序分为试验组和对照组，每组40例。试验组患者给予重组人组织型纤溶酶原激酶衍生物治疗，对照组患者给予尿激酶治疗。对比两组患者治疗后的血管再通率、心肌梗塞溶栓3级血流以及不良反应总发生率。结果 试验组患者治疗后，血管再通率为82.50%，心肌梗塞溶栓3级血流占比为67.50%；对照组患者治疗后，血管再通率为57.50%，心肌梗塞溶栓3级血流占比为42.50%，两组比较差异存在统计学意义（P<0.05）。试验组患者不良反应总发生率为10.00%，低于对照组患者的32.50%，差异存在统计学意义（P<0.05）。结论 在急性心肌梗死的溶栓治疗中，使用重组人组织型纤溶酶原激酶衍生物的效果良好，血管的再通率较高，心肌梗塞溶栓3级血流比例较大，且不良反应少，值得推广。

关键词：重组人组织型纤溶酶原激酶衍生物；溶栓治疗；急性心肌梗死

中图分类号：R542.22 文献标志码：A文章编号：2096-1413(2017)11-0026-02

Effect observation of reteplase for thrombolysis in the treatment of acute myocardial infarction
DONG Wei
(People's Hospital of Huayin City, Weinan 714200, China)

ABSTRACT: Objective To investigate the clinical effect of reteplase for thrombolysis in the treatment of acute myocardial infarction. Methods Eighty cases of acute myocardial infarction patients in our hospital from December 2012 to December 2015 were selected, all the patients were divided into experimental group and control group according to the hospitalization order, with 40 cases in each group. Patients in experimental group were given reteplase for thrombolysis, while the control group was given urokinase. After treatment, the rate of blood vessel patency, 3 levels of blood flow in myocardial infarction and adverse reaction incidence rate between two groups were compared. Results After treatment, the rate of blood vessel patency of the experimental group was 82.50%, 3 levels of blood flow in myocardial infarction of the experimental group was 67.50%, while in control group, the rate of blood vessel patency and 3 levels of blood flow in myocardial infarction were 57.50% and 42.50% respectively, the differences between two groups were statistically significant (P<0.05). The totalincidence rate of adverse reactions in experimental group was 10.00%, which was lower than 32.50% of the control group, the difference between the two groups was statistically significant (P<0.05). Conclusion In thrombolytic therapy for acute myocardial infarction, reteplase has good effect and with high blood vessel patency rate. It has a large proportion of 3 levels of blood flow in myocardial infarction and less adverse reactions, it is worth promotion in clinic.
KEYWORDS: reteplase; thrombolytic therapy; acute myocardial infarction

参考文献：
[1] 赵辉.重组人组织型纤溶酶原激酶衍生物溶栓治疗老年急性心肌梗死的临床研究[J].中华临床医师杂志:电子版,2011,5(20):6106-6108.

[2] 刘爱华,张娜,藏香银.重组人组织型纤溶酶原激酶衍生物溶栓治疗ST段抬高型急性心肌梗死的临床观察[J].中国医药导报,2014,11(21):68-70,84.
[3] 李淑娟,谢秀峰,陈凤英.重组人组织型纤溶酶原激酶衍生物静脉溶栓治疗急性心肌梗死的疗效观察[J].中西医结合心脑血管病杂志,2014,12(8):952-954.
[4] 邢慧萍,钟毅.重组人组织型纤溶酶原激酶衍生物在急性心肌梗死中溶栓疗效观察[J].中外医学研究,2011,9(25):1-2.
[5] 乔艳丽.尿激酶和重组人组织型纤溶酶原激酶衍生物溶栓治疗急性心肌梗死患者的疗效比较[J].中国医药指南,2016,14(6):24-25.
[6] 吉伟青.重组人组织型纤溶酶原激酶衍生物(rPA)在急性心肌梗死溶栓治疗中的作用分析[J].临床医学工程,2013,20(11):1407-1408.
[7] 吴帆.重组人组织型纤溶酶原激酶衍生物对急性心肌梗死患者BNP及临床疗效的影响[J].中国当代医药,2013,20(23):95-96,98.
[8] 张献敏,杨艮艮.重组人组织型纤溶酶原激酶衍生物在急性心肌梗死溶栓治疗中的应用效果[J].临床合理用药杂志,2014,7(5):31-32.
[9] 杜伟远,代旻升,张卫红.重组人组织型纤溶酶原激酶衍生物静脉溶栓治疗急性心肌梗死的临床研究[J].中外健康文摘,2010,7(29):181-182.
[10] 李敏.尿激酶与重组人组织型纤溶酶原激酶衍生物用于心肌梗死溶栓的疗效对比[J].世界临床医学,2016,10(7):92.